Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

Toshiaki Ohtsuka, Donald Buchsbaum, Patsy Oliver, Sharmila K. Makhija, Robert Kimberly, Tong Zhou

Research output: Contribution to journalArticle

132 Citations (Scopus)

Abstract

Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.

Original languageEnglish (US)
Pages (from-to)2034-2044
Number of pages11
JournalOncogene
Volume22
Issue number13
DOIs
StatePublished - Apr 3 2003
Externally publishedYes

Fingerprint

Death Domain Receptors
Cell Death
Apoptosis
Drug Therapy
Antibodies
Doxorubicin
Neoplasms
MAP Kinase Kinase 4
Mitochondrial Membrane Potential
Cell Surface Receptors
p38 Mitogen-Activated Protein Kinases
Caspases
Cytochromes c
Combination Drug Therapy
Tumor Cell Line
Cisplatin
Signal Transduction
Mitochondria
Monoclonal Antibodies
Therapeutics

Keywords

  • Apoptosis
  • Chemotherapy
  • JNK
  • Mitochondria
  • TRAIL receptor

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. / Ohtsuka, Toshiaki; Buchsbaum, Donald; Oliver, Patsy; Makhija, Sharmila K.; Kimberly, Robert; Zhou, Tong.

In: Oncogene, Vol. 22, No. 13, 03.04.2003, p. 2034-2044.

Research output: Contribution to journalArticle

Ohtsuka, Toshiaki ; Buchsbaum, Donald ; Oliver, Patsy ; Makhija, Sharmila K. ; Kimberly, Robert ; Zhou, Tong. / Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. In: Oncogene. 2003 ; Vol. 22, No. 13. pp. 2034-2044.
@article{5c027abe1c9b445aacc1722a41188614,
title = "Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway",
abstract = "Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.",
keywords = "Apoptosis, Chemotherapy, JNK, Mitochondria, TRAIL receptor",
author = "Toshiaki Ohtsuka and Donald Buchsbaum and Patsy Oliver and Makhija, {Sharmila K.} and Robert Kimberly and Tong Zhou",
year = "2003",
month = "4",
day = "3",
doi = "10.1038/sj.onc.1206290",
language = "English (US)",
volume = "22",
pages = "2034--2044",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "13",

}

TY - JOUR

T1 - Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway

AU - Ohtsuka, Toshiaki

AU - Buchsbaum, Donald

AU - Oliver, Patsy

AU - Makhija, Sharmila K.

AU - Kimberly, Robert

AU - Zhou, Tong

PY - 2003/4/3

Y1 - 2003/4/3

N2 - Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.

AB - Using two agonistic monoclonal antibodies specific for each death receptor of TRAIL, 2E12 (anti-human DR4) and TRA-8 (anti-human DR5), we examined the signal transduction of the death receptors in combination with or without chemotherapy agents such as Adriamycin (doxorubicin hydrochloride) and Cisplatin. Our results demonstrated that chemotherapy agents were able to enhance apoptosis-inducing activity of these antibodies against several different types of tumor cell lines through enhanced caspase activation. The combination of the antibodies and chemotherapy agents led to a synergistical activation of the JNK/p38 MAP kinase, which was mediated by MKK4. The combination also caused an increased release of cytochrome c and Smac/DIABLO from mitochondria in parallel with the profound loss of mitochondrial membrane potential. These results suggest that the enhanced activation of the JNK/p38 kinase and the mitochondrial apoptosis pathways play a crucial role in synergistic induction of the death receptor-mediated apoptosis by chemotherapy agents. Thus, the simultaneous targeting of cell surface death receptors with agonistic antibodies and the intracellular JNK/p38 and the mitochondrial death pathways with chemotherapy agents would enhance the efficacy and selectivity of both agents in cancer therapy.

KW - Apoptosis

KW - Chemotherapy

KW - JNK

KW - Mitochondria

KW - TRAIL receptor

UR - http://www.scopus.com/inward/record.url?scp=0037417134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037417134&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206290

DO - 10.1038/sj.onc.1206290

M3 - Article

C2 - 12673208

AN - SCOPUS:0037417134

VL - 22

SP - 2034

EP - 2044

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 13

ER -